• / Free eNewsletters & Magazine
  • / My Account

Alcohol

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. MillerCoors Delivers 22.2% First Quarter Underlying Net Income Growth

    MillerCoors Delivers 22.2% First Quarter Underlying Net Income Growth

  2. GEICO says safety is the name of the game this motorcycle season

    GEICO says safety is the name of the game this motorcycle season

  3. XenoPort to Release First Quarter Financial Results on May 5, 2016

    XenoPort to Release First Quarter Financial Results on May 5, 2016

  4. Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of ...

    Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  5. New York Insurers to Change Coverage of Hepatitis C Drugs

    New York Insurers to Change Coverage of Hepatitis C Drugs

  6. CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet

    CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet

  7. Increased Disposable Income to Boost the Global Left Ventricular Assist Device Market Through 2020, Says Technavio

    Increased Disposable Income to Boost the Global Left Ventricular Assist Device Market Through 2020, Says Technavio

  8. AAC Holdings Continues Expansion of Outpatient Strategy with Acquisition of Sober Living Beds in Arlington, Texas for $5.35 Million

    AAC Holdings Continues Expansion of Outpatient Strategy with Acquisition of Sober Living Beds in Arlington, Texas for $5.35 Million

  9. Seattle Genetics Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances at the American Association for Cancer Research (AACR) Annual Meeting

    Seattle Genetics Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances at the American Association for Cancer Research (AACR) Annual Meeting

  10. A4A Applauds Approval of Fourth Sustainable Alternative Jet Fuel Specification

    A4A Applauds Approval of Fourth Sustainable Alternative Jet Fuel Specification

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.